Results 61 to 70 of about 530,197 (354)
Evaluation of MMP‑2, MMP‑9, TIMP‑1, TIMP‑2, NGAL and MMP‑9/NGAL complex in urine and sera from patients with bladder cancer [PDF]
, 2015 The identification of biomarkers in urine or serum samples from patients with bladder cancer is urgently required for the development of non-invasive methods for the diagnosis of bladder carcinoma and to facilitate follow-up surveillance, to combat the ...Bruzzese, Dario, DI CARLO, Angelina, Ricci, Serena +2 morecore +1 more sourceAberrant expression of nuclear prothymosin α contributes to epithelial‐mesenchymal transition in lung cancer
Molecular Oncology, EarlyView.Nuclear prothymosin α inhibits epithelial‐mesenchymal transition (EMT) in lung cancer by increasing Smad7 acetylation and competing with Smad2 for binding to SNAI1, TWIST1, and ZEB1 promoters. In early‐stage cancer, ProT suppresses TGF‐β‐induced EMT, while its loss in the nucleus in late‐stage cancer leads to enhanced EMT and poor prognosis.Liyun Chen, Chung‐Teng Wang, Jia‐Ming Chang, Ai‐Li Shiau, Gia‐Shing Shieh, Yau‐Lin Tseng, Yi‐Ting Yen, Tang‐Hsiu Huang, Li‐Hsin Cheng, Yu‐Chih Wu, Chao‐Liang Wu, Bing‐Hua Su, Pensee Wu +12 morewiley +1 more sourceActivation of cGAS-STING Signal to Inhibit the Proliferation of Bladder Cancer: The Immune Effect of Cisplatin
Cells, 2022 Cisplatin is commonly used in neoadjuvant, adjuvant, and systemic therapy for advanced bladder cancer, but its immune-related mechanism is still unclear.Guanghou Fu, Yunfei Wu, Guanan Zhao, Xiaoyi Chen, Zhijie Xu, Junjie Sun, Junjie Tian, Zhengjun Cheng, Yue Shi, Baiye Jin +9 moredoaj +1 more sourceA multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. [PDF]
, 2010 We conducted a multi-stage, genome-wide association study of bladder cancer with a primary scan of 591,637 SNPs in 3,532 affected individuals (cases) and 5,120 controls of European descent from five studies followed by a replication strategy, which ...Aben, Katja K, Albanes, Demetrius, Allen, Naomi E, Allione, Alessandra, Andriole, Gerald, Baris, Dalsu, Benhamou, Simone, Besenbacher, Soren, Bishop, David T, Black, Amanda, Bolick, Sophia CE, Brennan, Paul, Bueno-de-Mesquita, H Bas, Burdett, Laurie, Cancel-Tassin, Geraldine, Canzian, Federico, Caporaso, Neil, Carrato, Alfredo, Chanock, Stephen J, Chatterjee, Nilanjan, Chen, Meng, Clavel-Chapelon, Francoise, Cortessis, Victoria K, Cussenot, Olivier, Czerniak, Bogdan, D García-Prats, María, De Vivo, Immaculata, Dietrich, Holger, Dinney, Colin P, Diver, W Ryan, Figueroa, Jonine D, Fletcher, Tony, Fraumeni, Joseph F, Fu, Yi-Ping, Gago-Dominguez, Manuela, Gapstur, Susan M, Garcia-Closas, Montserrat, García-Closas, Reina, Godfrey, Ashley, Golka, Klaus, Grubb, Robert, Guarrera, Simonetta, Gurzau, Eugen, Hengstler, Jan G, Hildebrandt, Michelle AT, Hoover, Robert N, Hunter, David J, Hutchinson, Amy, Jacobs, Eric J, Jacobs, Kevin B, Johnson, Alison, Karagas, Margaret R, Kiemeney, Lambertus A, Kiltie, Anne E, Knowles, Margaret A, Kogevinas, Manolis, Koppova, Kvetoslava, Kumar, Rajiv, Landi, Maria Teresa, Ljungberg, Borje, Lloreta, Josep, Makkinje, Remco R, Malats, Nuria, Matullo, Giuseppe, Mayordomo, Jose I, McGrath, Monica, Navarro, Carmen, Panico, Salvatore, Pike, Malcolm C, Polidoro, Silvia, Porru, Stefano, Prokunina-Olsson, Ludmila, Purdue, Mark P, Rafnar, Thorunn, Real, Francisco X, Riboli, Elio, Ricceri, Fulvio, Rothman, Nathaniel, Rudnai, Peter, Sacerdote, Carlotta, Sanchez, Manuel, Sanz-Velez, José I, Schned, Alan, Schwenn, Molly, Selinski, Silvia, Serra, Consol, Silverman, Debra T, Stefansson, Kari, Stern, Mariana C, Sulem, Patrick, Tardón, Adonina, Taylor, Jack A, Teo, Mark TW, Thun, Michael, Tjonneland, Anne, Trichopoulos, Dimitrios, Valdivia, Gabriel, Van Den Berg, David, Vermeulen, Sita H, Vineis, Paolo, Virtamo, Jarmo, Wang, Zhaoming, Weinstein, Stephanie J, Wheeler, William, Witjes, J Alfred, Wu, Xifeng, Xu, Zongli, Yang, Hushan, Yeager, Meredith, Yuan, Jian-Min +109 morecore +2 more sourcesThe subcellular distribution of phosphorylated Y‐box‐binding protein‐1 at S102 in colorectal cancer patients, stratified by KRAS mutational status and clinicopathological features
Molecular Oncology, EarlyView.This study identifies nuclear YB‐1 S102 phosphorylation as a marker associated with KRAS and FBXW7 mutations in colorectal cancer. Mutated KRAS correlates specifically with nuclear, not cytoplasmic, S102 YB‐1. These findings provide the first ex vivo evidence of this link in CRC and suggest future studies should assess the prognostic and therapeutic ...Konstanze Lettau, Stephan Forchhammer, Birgit Fehrenbacher, Lejla Mahmutovic, Marcus Scharpf, Gunnar Blumenstock, Martin Schaller, Irina Bonzheim, Shayan Khozooei, Mahmoud Toulany +9 morewiley +1 more sourceDiscrimination of bladder cancer cells from normal urothelial cells with high specificity and sensitivity:combined application of atomic force microscopy and modulated Raman spectroscopy [PDF]
, 2014 Atomic force microscopy (AFM) and modulated Raman spectroscopy (MRS) were used to discriminate between living normal human urothelial cells (SV-HUC-1) and bladder tumour cells (MGH-U1) with high specificity and sensitivity.Adya, Ashok K., Borger, Eva, Canetta, Elisabetta, Dholakia, Kishan, Herrington, Simon, Riches, Andrew +5 morecore +2 more sourcesFocus on bladder cancer [PDF]
Cancer Cell, 2004 Supported by NIH Specialized Programs of Research Excellence Grant in Genitourinary Cancer CA91846, and National Cancer Institute Grants CA16672, CA066723, and CA85078.Anita L. Sabichi, Bogdan Czerniak, Arlene O. Siefker-Radtke, Colin P.N. Dinney, Xifeng Wu, David J. McConkey, Liana Adam, H. Barton Grossman, Randall E. Millikan, Ashish M. Kamat, William F. Benedict, Tomasz Tuziak, Menashe Bar-Eli +12 moreopenaire +3 more sourcesTherapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cancer
Molecular Oncology, EarlyView.C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.Hannah G. McDonald, Anna M. Reagan, Charles J. Bailey, Mei Gao, Muqiang Gao, Angelica L. Solomon, Michael J. Cavnar, Prakash K. Pandalai, Mautin T. Barry‐Hundeyin, Megan M. Harper, Justin A. Rueckert, Ángela Turrero, Araceli Tobio, Anxo Vidal, Daniel Roca‐Lema, Elia Álvarez‐Coiradas, Pablo Garrido, Laureano Simón, Joseph Kim +18 morewiley +1 more sourceEnfortumab vedotin–related cutaneous toxicity correlates with overall survival in patients with urothelial cancer: a retrospective experience
Frontiers in OncologyIntroductionEnfortumab vedotin (EV) is an antibody drug conjugate approved for advanced urothelial cancer, consisting of a monomethyl auristatin E payload linked to a human monoclonal antibody targeting nectin-4.Evangelia Vlachou, Evangelia Vlachou, Burles Avner Johnson, Burles Avner Johnson, David McConkey, David McConkey, Yuezhou Jing, Andres Matoso, Andres Matoso, Andres Matoso, Andres Matoso, Noah M. Hahn, Noah M. Hahn, Noah M. Hahn, Jean Hoffman-Censits, Jean Hoffman-Censits, Jean Hoffman-Censits +16 moredoaj +1 more sourceAn evaluation of morphological and functional multi-parametric MRI sequences in classifying non-muscle and muscle invasive bladder cancer [PDF]
, 2017 Objectives: Our goal is to determine the ability of multi-parametric magnetic resonance imaging (mpMRI) to differentiate muscle invasive bladder cancer (MIBC) from non-muscle invasive bladder cancer (NMIBC).Barchetti, Giovanni, Carano, Davide, Catalano, Carlo, Catto, James, DE BERARDINIS, Ettore, DEL MONTE, Maurizio, Gallucci, Michele, Grompone, Marcello Domenico, Leonardo, Costantino, Panebianco, Valeria, Simone, Giuseppe +10 morecore +1 more source
